https://www.businesswire.com/news/home/20191114005780/en/

IRVINE, Calif.--(BUSINESS WIRE)--Nov 14, 2019--

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the third quarter ended September 30, 2019, and provided an update on operational initiatives.